| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/10/2004 | US6689754 Heterocyclic glycyl β-alanine derivatives |
| 02/10/2004 | US6689753 Alzheimer inhibitor peptide ia beta 5 (amino acid sequence 1leu-pro-phe-phe-asp) analog |
| 02/10/2004 | US6689752 Amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyls, and carboxy-terminal modifying groups include an amide, an alkyl amide, an aryl amide or a hydroxy; treating alzheimer's disease |
| 02/10/2004 | US6689751 Peptide comprising amino acid sequence 15 or 83 with alanine or alpha-aminoisobutyrate substitution |
| 02/10/2004 | US6689750 Bactericide compositions prepared and obtained from microccus varians |
| 02/10/2004 | US6689749 Voltage gated potassium channel blockers; interleukin-2 inhibitors; polypeptide having up to four cysteine based disulfide bonds |
| 02/10/2004 | US6689747 Use of insulin for the treatment of cartilagenous disorders |
| 02/10/2004 | US6689746 Antitumor agents |
| 02/10/2004 | US6689745 Agent for ameliorating pancreatic function disorder |
| 02/10/2004 | US6689744 Notch receptor agonists and uses |
| 02/10/2004 | US6689743 Bacillus thuringiensis isolates and toxins |
| 02/10/2004 | US6689607 Antibody for use in the treatment of aberrant cell proliferation and differentiation defects |
| 02/10/2004 | US6689598 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| 02/10/2004 | US6689597 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis |
| 02/10/2004 | US6689583 Chromatin regulator genes |
| 02/10/2004 | US6689582 Polynucleotide molecules encoding proteins having proteinase inhibitor activity |
| 02/10/2004 | US6689581 Potassium channel interactors and uses therefor |
| 02/10/2004 | US6689580 Growth factor |
| 02/10/2004 | US6689579 That stimulates b lymphocyte proliferation, differentiation, or survival; novel cytokine expressed by neutrophils; vectors, host cells |
| 02/10/2004 | US6689575 IκB kinase, subunits thereof, and methods of using same |
| 02/10/2004 | US6689562 Mammalian IAP gene family, primers, probes and detection methods |
| 02/10/2004 | US6689561 Isolated cdk4i gene (cdk4i=cyclin-dependent kinase 4 inhibitor), in which deletions or polymorphisms have been shown to cause susceptibility to certain cancers; detecting deletions or polymorphisms; kits, diagnosis |
| 02/10/2004 | US6689560 Inhibiting raf expression by expressing an antisense raf gene; inhibiting a cellular transformation phenotype induced by an oncogene |
| 02/10/2004 | US6689557 Method of identifying a substance that affects long term memory and CREM/CREB/ATF-1 subfamily members |
| 02/10/2004 | US6689404 Iodinated protein which includes at least phenylalanine or tryptophan; iodinated lactoglobulin |
| 02/10/2004 | US6689365 Follicle stimulating hormone, luteinizing hormone; varying ratios of lh activity as compared to fsh activity; fsh beta is linked through a linker to lh beta; the alpha subunit is downstream from both; fusion protein |
| 02/10/2004 | US6689363 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| 02/10/2004 | US6689362 Method for treating T-lineage leukemias and lymphomas using a CD7-specific monoclonal antibody (TXU-7) linked to the pokeweed antiviral protein (PAP) |
| 02/10/2004 | US6689359 Ligands, including antibodies, showing reactivity against endocrine cells |
| 02/10/2004 | US6689353 Stabilized with histidine, glycine and sucrose |
| 02/10/2004 | US6689352 Polypeptide |
| 02/10/2004 | US6689351 Use of GM-CSF to promote accelerated wound healing |
| 02/10/2004 | US6689338 Bioconjugates of nanoparticles as radiopharmaceuticals |
| 02/10/2004 | US6689337 Vitronectin receptor antagonist pharmaceuticals |
| 02/10/2004 | US6689121 Systems and methods for treating ischemia |
| 02/10/2004 | US6688311 Method for determining effect of a clostridial toxin upon a muscle |
| 02/10/2004 | US6688304 Inhaled insulin dosage control delivery enhanced by controlling total inhaled volume |
| 02/10/2004 | CA2297134C A novel process for preparing intermediates or inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof |
| 02/10/2004 | CA2274581C Oligonucleotide compositions and methods for the modulation of the expression of b7 protein |
| 02/10/2004 | CA2272854C Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives |
| 02/10/2004 | CA2214247C Modulators of amyloid aggregation |
| 02/10/2004 | CA2070061C Physiologically active polypeptide-containing pharmaceutical composition |
| 02/09/2004 | CA2421269A1 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 02/06/2004 | CA2436890A1 Pharmaceutical preparation with rna as hemostasis cofactor |
| 02/05/2004 | WO2004011902A2 Improved systems and methods for analysis of protein post-translational modification |
| 02/05/2004 | WO2004011680A1 Regulated aptamer therapeutics |
| 02/05/2004 | WO2004011651A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/05/2004 | WO2004011650A2 Antigens encoded by alternative reading frame from pathogenic viruses |
| 02/05/2004 | WO2004011647A1 Modified small interfering rna molecules and methods of use |
| 02/05/2004 | WO2004011632A2 Oligodendrocyte production from multipotent neural stem cells |
| 02/05/2004 | WO2004011624A2 Double stranded rna structures and constructs, and methods for generating and using the same |
| 02/05/2004 | WO2004011623A2 Antisense modulation of ptpra expression |
| 02/05/2004 | WO2004011620A2 Methods and compositions using polynucleotides and polypeptides of rank-associated inhibitor (rain) |
| 02/05/2004 | WO2004011617A2 Identification of a novel bitter taste receptor, t2r76 |
| 02/05/2004 | WO2004011615A2 USES OF CIRCADIAN GENE mPER2 |
| 02/05/2004 | WO2004011613A2 Composition & methods for treatment and screening |
| 02/05/2004 | WO2004011610A2 Antisense modulation of polo-like kinase expression |
| 02/05/2004 | WO2004011498A2 Long lasting natriuretic peptide derivatives |
| 02/05/2004 | WO2004011497A1 Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap) |
| 02/05/2004 | WO2004011495A1 Brca1-interacting protein |
| 02/05/2004 | WO2004011489A2 Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells |
| 02/05/2004 | WO2004011487A2 Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity |
| 02/05/2004 | WO2004011485A2 Stabilized bioactive peptides and methods of identification, synthesis, and use |
| 02/05/2004 | WO2004011484A2 Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion |
| 02/05/2004 | WO2004011483A2 Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof |
| 02/05/2004 | WO2004011476A1 Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer |
| 02/05/2004 | WO2004011098A2 Golf shaft with adjustable stiffness and frequency |
| 02/05/2004 | WO2004011060A2 Delivery of molecules and complexes to mammalian cells in vivo |
| 02/05/2004 | WO2004011029A2 Pharmaceutical compositions for penis enlargement |
| 02/05/2004 | WO2004011024A1 Pharmaceutical active ingredient preparations and medicaments that contain thrombin or have a thrombin-generating capacity |
| 02/05/2004 | WO2004011023A1 Pharmaceutically active substance preparations and drugs that are capable of generating thrombin and/or that contain thrombin |
| 02/05/2004 | WO2004011021A1 Method of enhancing and/or inducing neuronal migration using erythropoietin |
| 02/05/2004 | WO2004011019A1 Use of a proteasome inhibitor in the treatment of fibrotic diseases |
| 02/05/2004 | WO2004011018A2 Methods of identifying selective beta-1-adrenergic receptor antagonists |
| 02/05/2004 | WO2004010987A2 Use of s1p receptor agonists in heart diseases |
| 02/05/2004 | WO2004010968A1 Non-amphoteric glutathione derivative compositions for topical application |
| 02/05/2004 | WO2004010956A2 Antisense modulation of lar expression |
| 02/05/2004 | WO2004010954A2 Cardioprotective therapies based on enzymatic elimination of lipid peroxides by allene oxide synthase |
| 02/05/2004 | WO2004010951A2 Method of treating tumors |
| 02/05/2004 | WO2004010939A2 Methods of using non-human animal apoliprotein a-i protein |
| 02/05/2004 | WO2004010934A2 Methods for the use of neurotoxin in the treatment of urologic disorders |
| 02/05/2004 | WO2004010900A1 Devices delivering therapeutic agents and methods regarding the same |
| 02/05/2004 | WO2004010894A2 Ophthalmologic irrigation solutions and method |
| 02/05/2004 | WO2004010848A2 Oncogenes useful for the identification of urinary bladder cancer |
| 02/05/2004 | WO2003097871A3 Marker molecules associated with lung tumors |
| 02/05/2004 | WO2003094829A3 Pathogen vaccines and methods for using the same |
| 02/05/2004 | WO2003093816A3 Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr) |
| 02/05/2004 | WO2003093320A3 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses |
| 02/05/2004 | WO2003093305A3 Teneurin c-terminal associated peptides (tcap) and uses thereof |
| 02/05/2004 | WO2003089624A3 Fc receptor homolog, reagents, and uses thereof |
| 02/05/2004 | WO2003089001A8 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus |
| 02/05/2004 | WO2003088991A9 Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| 02/05/2004 | WO2003087818A3 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 02/05/2004 | WO2003087159A3 Modulators of the notch signalling pathway and uses thereof in medical treatment |
| 02/05/2004 | WO2003086461A3 Use of substances for treating tumors |
| 02/05/2004 | WO2003084996A3 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine |
| 02/05/2004 | WO2003084560A3 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| 02/05/2004 | WO2003083442A3 Life sciences business systems and methods |
| 02/05/2004 | WO2003082919A3 Ox40r binding agents |
| 02/05/2004 | WO2003082915A3 Xcrf polynucleotides and polypeptides and uses thereof |